Malignant Ascites in Critically Ill Cancer Patients

  • Cristina Prata AmendolaEmail author
  • Luís Gustavo Capochin Romagnolo
  • Raphael L. C. Araujo
Reference work entry


Ascites is characterized by the pathological accumulation of fluid in the peritoneal cavity. Malignant ascites is responsible for approximately 10% of all causes of ascites. Ten of 15% of patients with gastrointestinal cancer at some stage develop ascites, and up to 20% of all cases of malignance have unknown primary tumors. Usually it represents an important prognostic factor since most of time it is related to the carcinomatosis, which represents advanced stages or progression of disease in the most of malignancies. The accumulation of malignant cells and proteins from tumor in peritoneal cavity improve the intra-abdominal pressure. Moreover, the evolvement of other system as renal, hepatic, or respiratory can add significant morbidity to critic ill patients. The treatment of intra-abdominal hypertension in patients with ascites can be made puncture and facilitate by image-guided methods. This chapter approaches the main aspects of physiopathology, diagnosis, management, and prognosis of malign ascites in critic ill patients.


Malignant ascites Peritoneal cavity Carcinomatosis Peritoneum Accumulation of fluid Intra-abdominal malignance Intra-abdominal hypertension 


  1. 1.
    Amin MBES, Greene FL, et al. AJCC cancer staging manual. New York: Springer; 2017.CrossRefGoogle Scholar
  2. 2.
    Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRefGoogle Scholar
  3. 3.
    Araújo RL, Lopes G, Aisen M. Role of cytoreduction surgery with HIPEC in the management of peritoneal carcinomatosis from colorectal cancer and pseudomyxoma peritonei. Curr Colorectal Cancer Rep. 2015;11(3):99–104.CrossRefGoogle Scholar
  4. 4.
    Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9.CrossRefGoogle Scholar
  5. 5.
    Brook I. Intra-abdominal, retroperitoneal, and visceral abscesses in children. Eur J Pediatr Surg. 2004; 14(4):265–73.CrossRefGoogle Scholar
  6. 6.
    Chopra N, Kumar S, Chandra A. Malignant ascites: a review of pathogenesis and management. Open Access J Surg. 2017;2(5):555596.Google Scholar
  7. 7.
    Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16): 1646–54.CrossRefGoogle Scholar
  8. 8.
    Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, … Sugrue M. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013;39(7):1190–206.Google Scholar
  9. 9.
    Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manag. 1998;16(2):96–101.CrossRefGoogle Scholar
  10. 10.
    Maeda H, Kobayashi M, Sakamoto J. Evaluation and treatment of malignant ascites secondary to gastric cancer. World J Gastroenterol. 2015;21(39): 10936–47. ISSN 1007-9327CrossRefGoogle Scholar
  11. 11.
    Peter NG, Clark LR, Jaeger JR. Fitz-Hugh-Curtis syndrome: a diagnosis to consider in women with right upper quadrant pain. Cleve Clin J Med. 2004;71(3): 233–9.CrossRefGoogle Scholar
  12. 12.
    Rogers WK, Garcia L. Intraabdominal hypertension, abdominal compartment syndrome, and the open abdomen. Chest. 2018;153(1):238–50. ISSN 0012-3692CrossRefGoogle Scholar
  13. 13.
    Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1998; 8:1104.CrossRefGoogle Scholar
  14. 14.
    Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4(4):87.CrossRefGoogle Scholar
  15. 15.
    Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol. 2003;15(2): 59–72.CrossRefGoogle Scholar
  16. 16.
    Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017; 9:115–30.CrossRefGoogle Scholar
  17. 17.
    Townsend CM Jr, Daniel Beauchamp R, Mark Evers B, Mattox KL. Sabiston textbook of surgery: the biological basis of the modern surgical practice. 20th ed. Philadelphia: Elsevier; 2012.Google Scholar
  18. 18.
    Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Cristina Prata Amendola
    • 1
    Email author
  • Luís Gustavo Capochin Romagnolo
    • 1
  • Raphael L. C. Araujo
    • 1
  1. 1.Fundação Pio XII – Hospital de Câncer de BarretosBarretosBrazil

Personalised recommendations